文献速递白血病造血干细胞移植与细胞治疗

奎扎替尼作为异基因造血干细胞移植后急性髓系白血病缓解期维持治疗的1期研究结果

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
PubMed 文献 · Am J Hematol · 2017-11-17

这项两部分、1期、多中心、开放标签、序贯分组、剂量递增研究评估奎扎替尼用于FLT3-ITD突变急性髓系白血病异基因造血干细胞移植后维持治疗。13例受试者接受40 mg/d(DL1,n=7)或60 mg/d(DL2,n=6)口服给药,28天为一周期,最多24周期。研究显示耐受性可接受,与历史队列相比早期证据提示复发率降低;未确定最大耐受剂量,但选择60 mg/d作为持续每日给药最高剂量。

要点

  • DL1和DL2各1例发生剂量限制性毒性,分别为3级胃出血和3级贫血,需中断用药。
  • 10例(77%)接受奎扎替尼超过1年,5例(38%)完成24周期,4例(31%)因不良事件停药。
  • 最常见3/4级不良事件为中性粒细胞减少(23%)、贫血(15%)、白细胞减少(15%)、淋巴细胞减少(15%)和血小板减少(15%)。

核心结论

  • 奎扎替尼用于异基因造血干细胞移植后维持治疗显示出可接受的耐受性,与历史队列相比早期证据提示复发率降低。
  • 未确定最大耐受剂量,但基于复发/难治性急性髓系白血病中每日30 mg与60 mg给药的随机比较,选择60 mg每日作为持续每日给药的最高剂量。

研究设计与样本

  • 两部分、1期、多中心、开放标签、序贯分组、剂量递增研究。
  • 13例异基因造血干细胞移植后形态学缓解的FLT3-ITD突变急性髓系白血病受试者。
  • 受试者接受奎扎替尼二盐酸盐40 mg/d(DL1;n=7)或60 mg/d(DL2;n=6)口服,28天为一周期,最多24周期。

主要发现

  • DL1中1例和DL2中1例发生剂量限制性毒性,分别需中断用药(3级胃出血和3级贫血)。
  • 10例(77%)接受奎扎替尼超过1年;5例(38%)完成24周期;4例(31%)因不良事件停药;1例(8%)在第1周期复发并停止治疗。
  • 最常见3/4级不良事件为中性粒细胞减少(23%)、贫血(15%)、白细胞减少(15%)、淋巴细胞减少(15%)和血小板减少(15%)。
  • 所有受试者均接受人类白细胞抗原(HLA)匹配的异基因造血干细胞移植;中位年龄43岁。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

FLT3-ITD-mutated acute myeloid leukemia (AML) has very high risk of relapse and is associated with poor outcome following allogeneic hematopoietic-cell transplant (allo-HCT). This two-part, phase 1, multicenter, open-label, sequential-group, dose-escalation study aimed to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and safety/tolerability of quizartinib, a selective and highly potent FLT3 inhibitor, when administered as maintenance therapy after allo-HCT. Thirteen subjects with documented FLT3-ITD-mutated AML in morphological remission following allo-HCT received one of two quizartinib dihydrochloride dose levels (DL): 40 mg/d (DL1; n = 7) and 60 mg/d (DL2; n = 6), administered orally in 28-day cycles for up to 24 cycles. Median age of participants was 43 years. All subjects received human leukocyte antigen (HLA)-matched allo-HCT. One subject treated at DL1 and 1 treated at DL2 had DLTs that required drug interruption (grade 3 gastric hemorrhage and grade 3 anemia, respectively). Ten subjects (77%) received quizartinib for >1 year; 5 (38%) completed 24 cycles. Four subjects (31%) discontinued quizartinib due to adverse events. One subject (8%) experienced relapse during cycle 1 and discontinued treatment. Most common grade 3/4 adverse events were neutropenia (23%), anemia (15%), leukopenia (15%), lymphopenia (15%), and thrombocytopenia (15%). This study demonstrated acceptable tolerability and early evidence of reduced relapse rate following allo-HCT with quizartinib maintenance compared to historical cohorts. No MTD was identified, but 60 mg daily was selected as highest dose for continuous daily administration based on randomized comparison of daily 30 and 60 mg doses in relapsed/refractory AML.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Sandmaier BM, Khaled S, Oran B, et al. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol. 2017. PMID: 29090473. doi:10.1002/ajh.24959

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。